Participants 69 100 3
advanced, life-limiting illness
Participants 147 178 4
patients with limited prognosis
Participants 389 426 4
patients with limited life expectancy
Participants 528 567 5
patients in the palliative care setting
Participants 680 959 9
Eligibility included adults with an estimated life expectancy of between 1 month and 1 year, statin therapy for 3 months or more for primary or secondary prevention of cardiovascular disease, recent deterioration in functional status, and no recent active cardiovascular disease.
Participants 1083 1141 3
The study was conducted from June 3, 2011, to May 2, 2013.
Participants 1616 1751 6
A total of 381 patients were enrolled; 189 of these were randomized to discontinue statins, and 192 were randomized to continue therapy
Participants 1753 1864 4
Mean (SD) age was 74.1 (11.6) years, 22.0% of the participants were cognitively impaired, and 48.8% had cancer.
